Skip Content
You are currently on the new version of our website. Access the old version .
BiomedicinesBiomedicines
  • This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
  • Review
  • Open Access

4 February 2026

Cannabinoid Effects of Metamizol/Dipyrone: A Possible Second Life in Pediatric Anesthesia for a Vintage Drug

,
,
,
,
,
,
,
,
1
Department of Anesthesia, Critical Care and Pain Medicine, ARCO, Ospedale Pediatrico Bambino Gesù IRCCS, Piazza S. Onofrio 4, 00165 Rome, Italy
2
Department of Life, Health and Environmental Sciences (MeSVA), University of L’Aquila, Piazzale Salvatore Tommasi 1, Blocco 11, Coppito, 67010 L’Aquila, Italy
3
Department of Medical and Surgical Sciences, Anesthesia and Intensive Care, “Magna Graecia” University, Viale Europa, 88100 Catanzaro, Italy
4
Surgery Unit, Bios Medical Center, Via Domenico Chelini 39, 00197 Rome, Italy
This article belongs to the Special Issue Advances in Pain Management: Exploring Molecular Mechanisms and Novel Therapies

Abstract

Background: Metamizol (dipyrone) is a widely used analgesic and antipyretic drug in several European countries, particularly for postoperative pain management in both adult and pediatric populations. Methods: A narrative literature review was conducted to evaluate the efficacy, safety, and pharmacological mechanisms of metamizol in postoperative pain management. A comprehensive search of PubMed, Scopus, and the Cochrane Library was performed, and included articles published up to 2024. Search terms included metamizol, dipyrone and children. Results: The available evidence indicates that metamizol provides effective postoperative analgesia, with an efficacy comparable to that of other non-steroidal anti-inflammatory drugs and paracetamol. Pediatric studies similarly support its effectiveness in postoperative settings. Regarding safety, short-term use of metamizol appears to be well tolerated, with a low incidence of serious adverse events. Mechanistic studies suggest that metamizol exerts analgesic effects through a multimodal pathway, involving not only cyclo-oxygenase inhibition but also modulation of opioid and endocannabinoid systems. Conclusions: Metamizol represents an effective and generally well-tolerated option for short-term postoperative pain management in both adults and children when used under appropriate clinical monitoring. Current evidence supports a favorable benefit-to-risk balance for short-term use while highlighting the need for caution during prolonged therapy. Further large-scale, prospective studies are warranted to better define rare adverse events, clarify interindividual risk factors, and refine the understanding of their non-classical mechanisms of action.

Article Metrics

Citations

Article Access Statistics

Article metric data becomes available approximately 24 hours after publication online.